Posted by Michael Wonder on 07 Sep 2018
ICER releases draft evidence report on medications for treatment of opioid use disorder
7 September 2018 - Public comment period now open until 4 October 2018; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a draft evidence report assessing the comparative clinical effectiveness and value of medications for addiction treatment used for individuals with opioid use disorder. The draft report will be open to public comment until 5pm ET on 4 October 2018.
ICER’s report assesses the effectiveness and value of a buprenorphine implant (Probuphine, Titan), an extended-release naltrexone injection (Vivitrol, Alkermes), and two extended-release buprenorphine injections: Sublocade (Indivior) and CAM2038 (Braeburn), an investigational agent currently under FDA review. The report will be subject to deliberation during a public meeting of the New England Comparative Effectiveness Public Advisory Council, one of ICER’s three independent evidence appraisal committees, on 8 November 2018.
